Truist Financial
GALT icon

Truist Financial’s Galectin Therapeutics GALT Stock Holding History

Truist Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Hold
68,000
– – ﹤0.01% 2508
2026
Q1 		$190K Hold
68,000
– – ﹤0.01% 2668
2025
Q4 		$283K Hold
68,000
– – ﹤0.01% 2371
2025
Q3 		$288K Hold
68,000
– – ﹤0.01% 2345
2025
Q2 		$143K Buy
+68,000
New +$102K ﹤0.01% 2464

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Truist Financial's GALT Position: Q2 2026 in Review

Truist Financial held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 68,000 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

Truist Financial first reported a position in GALT in Q2 2025 and has held it in 5 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Truist Financial held 68,000 shares of Galectin Therapeutics worth $316K as of Q2 2026.
  • Truist Financial left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2508 holding.
  • Truist Financial first reported a position in Galectin Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.